摘要
目的:探讨局部进展期乳腺癌新辅助化疗前后血清CA15-3水平变化及其与疗效的关系。方法:2002年-2006年应用CEF(环磷酰胺+表阿霉素+氟尿嘧啶)方案对96例IIb-III期乳腺癌患者进行新辅助化疗。28天为1个周期,新辅助化疗2个周期后评价疗效。于治疗前1天及治疗2周期后采外周静脉血5ml,用电化学发光免疫法检测血清CA15-3水平。结果:新辅助化疗总有效率为47.9%(46/96),其中38例(39.6%)降低了临床分期,完全缓解7例,部分缓解39例,无疾病进展者。96例乳腺癌患者化疗前CA15-3阳性率为64.6%(62/96)。CA15-3阳性组和阴性组总有效率分别为45.2%(28/62)、52.9%(18/34),无显著性差异(P>0.05)。化疗前血清CA15-3水平为45.8±6.3;化疗后为32.5±6.8,较化疗前显著下降(P<0.05)。其中临床完全缓解和部分缓解患者血清CA15-3水平化疗后较化疗前均有一定程度下降(P<0.05);而病情稳定患者血清CA15-3水平较化疗前无显著下降(P>0.05)。结论:新辅助化疗前后血清CA15-3水平变化与临床疗效有一定的相关性,动态监测血清CA15-3可预测疗效。
Objective:To investigate the relationship between the variation of serum CA15 -3 level and curative efficacy of neoadjuvant chemotherapy in local advanced breast cancer(LABC). Methods: During the period 2002 - 2006, 96 patients with stage Ⅱb - Ⅲ breast cancer were treated with CEF regimen for 2 cycles every 28 days. Accroding to the effect standard suggested by WHO efficacy was evaluated after two cycles of neoadjuvant chemotherapy. Patients received cyclophosphamide (CTX) 500 mg/m^2 on day1,8; epimbincin (EPI) 50 mg/m^2 on day1,8; 5 - fluorouracil (5 -Fu) 500 mg/m^2 on day1,8. The serum CA15 -3 level was measured by electrochemil immunoassay (ECLI) before chemotherapy and after 2 cycles of chemotherapy. Results: The overall response rate (RR) of the primary tumor was 47.9% (46/96). There was no disease progressive ( PD), complete response (CR) in 7 cases, partial response (PR) in 39 cases. The positive rate of CA15 - 3 before chemotherapy was 64.6% (62/ 96). The overall response rate in CA15 -3 positive and CA15 -3 negative breast cancer were 45.2% (28/62) and 52.9% (18/34) respectively, which was no significant difference. CA15 -3 level before chemotherapy and after chemotherapy were 45.8 ± 6.3 and 32.5 ± 6.8 in 96 local advanced breast cancer patients. CA15 - 3 level after chemotherapy was significantly lower than before chemotherapy in both complete response and partial response patients, while it was no significant change in stable disease cases. Conclusion: There is a significant correlation between the variation of serum CA15 -3 level and curative efficacy of neoadjuvant chemotherapy in LABC patients. Sequential monitoring of serum CA15 -3 level is valuble for predicting curative effect.
出处
《现代肿瘤医学》
CAS
2008年第7期1158-1160,共3页
Journal of Modern Oncology
关键词
乳腺肿瘤
新辅助化疗
CA15—3
临床疗效
电化学发光免疫法
breast cancer
neoadjuvant chemotherapy
CA15 -3
curative effect
electrochemiluminescence immunoassay